AlphaRx Completes Lyophilization Process for Zysolin(TM)

MARKHAM, ON, Aug. 17 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB:ALRX.OB -
News), an emerging biopharmaceutical company utilizing proprietary drug
delivery technology to develop novel formulations of drugs, is pleased to
announce that it has completed the lyophilization process for Zysolin(TM),
allowing the company to proceed to clinical batch material manufacturing for
human trials. This process has been solely developed by AlphaRx's scientists
and the resulting formulations have been successfully tested in animal studies
conducted by the U.S. Army under a Material Transfer Agreement.
"This is a technological milestone for AlphaRx and the entire nanomedicine
industry," commented Dr. Joseph Schwarz, AlphaRx's Chief Scientist. "It is
well known that many FDA approved ingredients used in nanomedicine
formulations can not be readily lyophilized, representing the major obstacle
to their therapeutic development, a critical step which we have overcome."
Many biotechnology products require lyophilization, a process of freeze-drying
sterile solutions to permit a shelf stable dosage form. By removing the water
from the material and sealing the material in a vial, it can be easily stored,
shipped, and later reconstituted to its original form for administration.
Zysolin(TM) is protected by 3 U.S. patents pending and the Company plans to
file a new patent application to protect this new process.

About Zysolin(TM)

Zysolin(TM) is a Tobramycin compound, encapsulated in AlphaRx's Nano Drug
Delivery Platform, intended for the adjunctive treatment of Gram-negative
pneumonia in intubated and mechanically-ventilated patients. Zysolin(TM)
improves the intracellular activity of Tobramycin - in layman's term,
increasing the drug concentration of Tobramycin inside human macrophages, thus
improving its antibacterial activity against intracellular Klebsiella,
Pseudomondas aeruginosa and Staphylococcus bacterial strains in pneumonia
patients. The active ingredient in Zysolin(TM), Tobramycin, has a
long-standing and proven clinical treatment record. Delivered by inhalation,
using proprietary nanotechnology developed by AlphaRx, the company believes
Zysolin(TM) will have an attractive safety, tolerability and efficacy profile
when compared to injectible Tobramycin.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven
therapies by reformulating FDA approved and marketed drugs which through the
application of its proprietary site-specific nano drug delivery technology,
offers improved medical benefits and a potential for significant commercial
product development.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and
pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act
of 1995 and involve risks and uncertainties that may individually or mutually
impact the matters herein described, including but not limited to product
development and acceptance, manufacturing, competition, regulatory and/or
other factors, which are outside the control of the Company.

This press release is available on the company's official on-line investor
relations site for investor commentary, feedback and questions.

SOURCE AlphaRx Inc.